From the Q1 conference call, I quote:"Look, I think we're very...

From the Q1 conference call, I quote:

"Look, I think we're very excited to have Novartis as our strategic partner on many fronts, on many issues. I think, first of all, the fact that we have now opened a focus -- a major focus on respiratory medicine is, first and foremost, the real value to the strategic collaboration. Six months ago, we didn't have any focus on respiratory medicine. Now this becomes a leading franchise for us.
Novartis' deep expertise in this space, their strength in clinical development, their strength in regulatory development, their strength in cell and gene therapy and their know-how in manufacturing of cellular therapies are all going to be tremendous assets for us as a partner. We will continue to optimize the manufacturing, the potency assays, the attributes of the product and focus particularly as it needs to be on COVID-19 ARDS."

and this:
"And as partners, Novartis will assist us and provide us their input. And I think they will add greater to our interactions with the FDA on multiple fronts."

Mesoblast (MESO) Q1 2021 Earnings Call Transcript

https://www.google.com.au/amp/s/www.********/amp/earnings/call-transcripts/2020/11/23/mesoblast-meso-q1-2021-earnings-call-transcript/

GLTA!